2-[5-[6-[4-[(4-Tert-butylphenyl)methylcarbamoyl-ethylamino]-4-iminobutyl]pyrimidin-4-yl]-2-ethoxyphenyl]acetic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-[5-[6-[4-[(4-Tert-butylphenyl)methylcarbamoyl-ethylamino]-4-iminobutyl]pyrimidin-4-yl]-2-ethoxyphenyl]acetic acid
• 英文别名: 2-[5-[6-[4-[(4-tert-butylphenyl)methylcarbamoyl-ethylamino]-4-iminobutyl]pyrimidin-4-yl]-2-ethoxyphenyl]acetic acid
• 化学式: C₃₂H₄₁N₅O₄
• 分子量: 559.7
• InChiKey: OIKVBWUYRQNALK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  41
• 可旋转键数：
  14
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  129
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• [EN] TRIAZOLONE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE TRIAZOLONE ET LEURS UTILISATIONS
  申请人：INCEPTION 2 INC

  公开号：WO2014099503A1

  公开（公告）日：2014-06-26

  The invention disclosed herein is directed to compounds of Formula I [Formula should be inserted here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARa antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.

  本发明涉及式I的化合物[应在此处插入公式]及其药学上可接受的盐，用于治疗前列腺、乳腺、结肠、胰腺、人类慢性淋巴细胞白血病、黑色素瘤和其他癌症。该发明还包括含有式I化合物的治疗有效量或其药学上可接受的盐的药物组合物。本发明还涉及治疗前列腺、乳腺、卵巢、肝脏、肾脏、结肠、胰腺、人类慢性淋巴细胞白血病、黑色素瘤和其他癌症的方法。本发明还涉及治疗前列腺、乳腺、结肠、胰腺、慢性淋巴细胞白血病、黑色素瘤和其他癌症的方法，包括给予选择性PPARa拮抗剂的治疗有效量。该发明的化合物和药物组合物还可用于治疗病毒感染，如HCV感染和HIV感染。